Loading...
•
Sep 30
CRISPR Therapeutics Q3 2025 Earnings Report
CRISPR Therapeutics reported a net loss in Q3 2025 as R&D and collaboration expenses remained high despite a modest increase in grant revenue.
Key Takeaways
CRISPR Therapeutics posted a net loss of $106.4 million in Q3 2025 on revenue of $889,000. While R&D costs declined year-over-year, collaboration expenses rose significantly. The company maintains a strong cash position of $1.9 billion and continues advancing multiple clinical programs.
Revenue reached $889,000 in Q3 2025, solely from grant income.
Net loss widened to $106.4 million compared to $85.9 million in Q3 2024.
Cash, cash equivalents, and marketable securities totaled $1.94 billion at quarter end.
R&D expenses decreased to $58.9 million, while collaboration expenses surged to $57.1 million.
CRISPR Therapeutics
CRISPR Therapeutics
CRISPR Therapeutics Revenue by Segment
Revenue by Segment
Grant Revenue
CapyFin.com Forward Guidance
The company projects continued momentum across its clinical pipeline, with CASGEVY revenue expected to exceed $100 million in 2025 and significant growth forecasted for 2026.
Positive Outlook
- Strong CASGEVY adoption with 39 patients infused to date.
- Enrollment completed in global pediatric Phase 3 studies for exa-cel.
- Positive Phase 1 data for CTX310 presented and published.
- First patient dosed in Phase 2 trial of SRSD107.
- Robust cash position supports long-term pipeline development.
Challenges Ahead
- Continued net losses despite clinical progress.
- High collaboration expenses impacting profitability.
- Minimal revenue outside of grants in Q3 2025.
- R&D costs, while reduced, remain a substantial burden.
- No updates on commercialization revenue from CASGEVY reported in Q3.